Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney.
Small vessel vasculitis of the kidney is an inflammatory disorder that results in glomerulonephritis. Current treatment regimes have proved effective, with patient survival rates of 80% at five years. Of the 20% that die, a significant number of deaths are due to the side effects of therapies, and immunosuppression. A more tailored approach is required that targets the cells involved rather than generally restraining the immune system. This can only be achieved by increasing our knowledge of disease pathogenesis.
Williams
Julie M
JM
Renal Immunobiology, Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. J.M.Williams.MED@bham.ac.uk
D000818:Animals; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy* / Q000276:immunology; D018375:Neutrophil Activation / Q000187:drug effects; D020556:Neutrophil Infiltration / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators